Integrated genomic analyses of ovarian carcinoma.

PubWeight™: 47.72‹?› | Rank: Top 0.01% | All-Time Top 1000

🔗 View Article (PMC 3163504)

Published in Nature on June 29, 2011

Authors

Cancer Genome Atlas Research Network

Associated clinical trials:

A Study of Coti-2 for the Treatment of Advanced or Recurrent Gynecologic Malignancies (COTI2-101) | NCT02433626

Bortezomib and Pegylated Liposomal Doxorubicin in BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer Patients | NCT03509246

Phenotypic Characterization Tumor-infiltrating Lymphocytes at Diagnosis and After Chemotherapy in Ovarian Cancer (TILsOV-1805) | NCT03922776

Articles citing this

(truncated to the top 100)

An integrated map of genetic variation from 1,092 human genomes. Nature (2012) 59.82

Comprehensive molecular portraits of human breast tumours. Nature (2012) 47.39

Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med (2012) 44.56

Comprehensive molecular characterization of human colon and rectal cancer. Nature (2012) 34.13

The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov (2012) 26.98

Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature (2013) 20.16

Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal (2013) 19.54

Comprehensive genomic characterization of squamous cell lung cancers. Nature (2012) 18.90

The mutational landscape of head and neck squamous cell carcinoma. Science (2011) 16.88

Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol (2013) 16.13

VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res (2012) 15.90

Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet (2012) 15.21

Mutational landscape and significance across 12 major cancer types. Nature (2013) 14.91

Integrated genomic characterization of endometrial carcinoma. Nature (2013) 14.29

Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature (2013) 13.60

A landscape of driver mutations in melanoma. Cell (2012) 12.61

Personal omics profiling reveals dynamic molecular and medical phenotypes. Cell (2012) 12.32

The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature (2012) 11.91

The mutational landscape of lethal castration-resistant prostate cancer. Nature (2012) 11.82

The somatic genomic landscape of glioblastoma. Cell (2013) 11.73

Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell (2012) 11.69

The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet (2013) 11.29

SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med (2011) 11.07

Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol (2012) 10.87

Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet (2012) 9.93

Mutual exclusivity analysis identifies oncogenic network modules. Genome Res (2011) 7.22

Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA (2011) 6.81

Clonal architecture of secondary acute myeloid leukemia. N Engl J Med (2012) 6.71

Emerging landscape of oncogenic signatures across human cancers. Nat Genet (2013) 6.48

A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med (2013) 6.09

Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med (2011) 5.82

Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. Nat Genet (2011) 5.67

Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer (2011) 5.28

Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet (2012) 5.28

The DNA damage response and cancer therapy. Nature (2012) 5.25

Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat Genet (2012) 4.82

MuSiC: identifying mutational significance in cancer genomes. Genome Res (2012) 4.73

Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet (2013) 4.48

MicroRNA profiling: approaches and considerations. Nat Rev Genet (2012) 4.39

Evaluating cell lines as tumour models by comparison of genomic profiles. Nat Commun (2013) 4.35

Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35

Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell (2014) 4.17

Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proc Natl Acad Sci U S A (2011) 4.15

Whole genomes redefine the mutational landscape of pancreatic cancer. Nature (2015) 4.01

Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci U S A (2011) 3.99

A Tumor suppressor complex with GAP activity for the Rag GTPases that signal amino acid sufficiency to mTORC1. Science (2013) 3.96

BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol (2012) 3.86

Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA (2012) 3.85

Cancer genetics and epigenetics: two sides of the same coin? Cancer Cell (2012) 3.65

Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest (2012) 3.64

Exome sequencing of liver fluke-associated cholangiocarcinoma. Nat Genet (2012) 3.63

Proteogenomic characterization of human colon and rectal cancer. Nature (2014) 3.61

Development of PI3K inhibitors: lessons learned from early clinical trials. Nat Rev Clin Oncol (2013) 3.57

GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet (2013) 3.42

Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell (2014) 3.41

Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res (2013) 3.25

Network-based stratification of tumor mutations. Nat Methods (2013) 3.12

Organoid cultures derived from patients with advanced prostate cancer. Cell (2014) 3.12

Whole-genome characterization of chemoresistant ovarian cancer. Nature (2015) 3.06

Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. Proc Natl Acad Sci U S A (2012) 3.06

Interplay between the cancer genome and epigenome. Cell (2013) 3.05

Medulloblastomics: the end of the beginning. Nat Rev Cancer (2012) 3.01

Integrative annotation of variants from 1092 humans: application to cancer genomics. Science (2013) 2.98

Functional impact bias reveals cancer drivers. Nucleic Acids Res (2012) 2.96

Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun (2013) 2.94

Pan-cancer network analysis identifies combinations of rare somatic mutations across pathways and protein complexes. Nat Genet (2014) 2.91

TSGene: a web resource for tumor suppressor genes. Nucleic Acids Res (2012) 2.90

ContEst: estimating cross-contamination of human samples in next-generation sequencing data. Bioinformatics (2011) 2.90

Personalized genomic analyses for cancer mutation discovery and interpretation. Sci Transl Med (2015) 2.88

Integrative genomic analyses reveal clinically relevant long noncoding RNAs in human cancer. Nat Struct Mol Biol (2013) 2.84

Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models. Cancer Cell (2013) 2.81

Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. Nature (2014) 2.81

Ovarian surface epithelium at the junction area contains a cancer-prone stem cell niche. Nature (2013) 2.78

Integrated morphologic analysis for the identification and characterization of disease subtypes. J Am Med Inform Assoc (2012) 2.68

DNA replication timing and long-range DNA interactions predict mutational landscapes of cancer genomes. Nat Biotechnol (2011) 2.62

Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation. Nat Genet (2013) 2.59

Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers. Sci Transl Med (2013) 2.58

Comprehensive literature review and statistical considerations for microarray meta-analysis. Nucleic Acids Res (2012) 2.54

Allele-specific p53 mutant reactivation. Cancer Cell (2012) 2.51

Emerging patterns of somatic mutations in cancer. Nat Rev Genet (2013) 2.50

Essential gene profiles in breast, pancreatic, and ovarian cancer cells. Cancer Discov (2011) 2.49

The landscape of kinase fusions in cancer. Nat Commun (2014) 2.48

The Pan-Cancer analysis of pseudogene expression reveals biologically and clinically relevant tumour subtypes. Nat Commun (2014) 2.48

FAK in cancer: mechanistic findings and clinical applications. Nat Rev Cancer (2014) 2.46

Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc Natl Acad Sci U S A (2014) 2.46

Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma. Science (2014) 2.42

A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers. J Clin Invest (2012) 2.42

Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia. Nat Genet (2013) 2.38

Launching genomics into the cloud: deployment of Mercury, a next generation sequence analysis pipeline. BMC Bioinformatics (2014) 2.37

Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling. J Pathol (2013) 2.35

Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell (2013) 2.34

Next-generation sequencing for cancer diagnostics: a practical perspective. Clin Biochem Rev (2011) 2.31

GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics (2013) 2.29

Highly multiplexed single-cell analysis of formalin-fixed, paraffin-embedded cancer tissue. Proc Natl Acad Sci U S A (2013) 2.29

Antibiotics that target mitochondria effectively eradicate cancer stem cells, across multiple tumor types: treating cancer like an infectious disease. Oncotarget (2015) 2.28

Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer. Genome Res (2012) 2.27

Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis. Cancer Res (2012) 2.26

A pan-cancer proteomic perspective on The Cancer Genome Atlas. Nat Commun (2014) 2.25

Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol (2013) 2.24

BRCA1 functions independently of homologous recombination in DNA interstrand crosslink repair. Mol Cell (2012) 2.21

Articles cited by this

Cancer statistics, 2010. CA Cancer J Clin (2010) 103.28

Cancer statistics, 2009. CA Cancer J Clin (2009) 83.57

Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature (2008) 75.40

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 39.09

The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88

Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02

Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing. Nat Biotechnol (2009) 27.17

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature (2005) 26.32

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med (2009) 24.75

Human Protein Reference Database--2009 update. Nucleic Acids Res (2008) 21.25

Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A (2007) 18.83

The Catalogue of Somatic Mutations in Cancer (COSMIC). Curr Protoc Hum Genet (2008) 16.09

ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med (2010) 13.07

PID: the Pathway Interaction Database. Nucleic Acids Res (2008) 12.92

Mendelian Inheritance in Man and its online version, OMIM. Am J Hum Genet (2007) 9.61

The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer (2009) 9.01

Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM. Bioinformatics (2010) 8.44

Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res (2008) 8.17

The emerging roles of forkhead box (Fox) proteins in cancer. Nat Rev Cancer (2007) 8.05

Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst (2006) 6.73

Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst (2000) 6.38

Retracted An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol (2007) 5.77

BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer (2005) 5.57

Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol (2009) 5.37

Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol (2010) 5.23

Cancer-specific high-throughput annotation of somatic mutations: computational prediction of driver missense mutations. Cancer Res (2009) 4.92

The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers. Nat Med (2004) 4.69

Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med (2009) 4.68

Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J Clin Oncol (2000) 4.48

Hybrid selection of discrete genomic intervals on custom-designed microarrays for massively parallel sequencing. Nat Protoc (2009) 4.45

A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. Cancer Res (2008) 4.05

Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol (2009) 3.90

The cell of origin of ovarian epithelial tumours. Lancet Oncol (2008) 3.74

Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis. J Clin Oncol (2008) 3.74

Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas. Clin Cancer Res (2009) 3.45

Relative frequency of primary ovarian neoplasms: a 10-year review. Obstet Gynecol (1989) 3.24

The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol (2004) 2.95

K-ras mutations in mucinous ovarian tumors: a clinicopathologic and molecular study of 95 cases. Cancer (1997) 2.60

Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer. Cancer (2010) 2.52

Prioritization of driver mutations in pancreatic cancer using cancer-specific high-throughput annotation of somatic mutations (CHASM). Cancer Biol Ther (2010) 2.33

Pro-proliferative FoxM1 is a target of p53-mediated repression. Oncogene (2009) 2.32

Identification and characterization of the CDK12/cyclin L1 complex involved in alternative splicing regulation. Mol Cell Biol (2006) 2.30

Jagged-1 and Notch3 juxtacrine loop regulates ovarian tumor growth and adhesion. Cancer Res (2008) 2.26

Gene expression profiles of luteal phase fallopian tube epithelium from BRCA mutation carriers resemble high-grade serous carcinoma. Clin Cancer Res (2008) 2.23

BRCA1 CpG island hypermethylation predicts sensitivity to poly(adenosine diphosphate)-ribose polymerase inhibitors. J Clin Oncol (2010) 2.18

Activating and inactivating mutations in the human GNAS1 gene. Hum Mutat (2000) 2.09

Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group. J Clin Oncol (2009) 2.07

Deletion of Forkhead Box M1 transcription factor from respiratory epithelial cells inhibits pulmonary tumorigenesis. PLoS One (2009) 1.93

p53 mutation is infrequent in clear cell carcinoma of the ovary. Gynecol Oncol (2001) 1.83

Articles by these authors

Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature (2008) 75.40

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 39.09

Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med (2013) 19.87

Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell (2010) 16.12

Integrated genomic characterization of endometrial carcinoma. Nature (2013) 14.29

Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature (2013) 13.60

Comprehensive molecular characterization of gastric adenocarcinoma. Nature (2014) 11.93

Comprehensive molecular profiling of lung adenocarcinoma. Nature (2014) 11.02

Comprehensive molecular characterization of urothelial bladder carcinoma. Nature (2014) 8.48

Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71

Landscape of somatic retrotransposition in human cancers. Science (2012) 4.37

Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell (2014) 4.17

Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA (2012) 3.85

Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest (2012) 3.64

The Molecular Taxonomy of Primary Prostate Cancer. Cell (2015) 3.29

Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00

Integrated genomic characterization of oesophageal carcinoma. Nature (2017) 2.76

The somatic genomic landscape of chromophobe renal cell carcinoma. Cancer Cell (2014) 2.21

Integrated analyses of microRNAs demonstrate their widespread influence on gene expression in high-grade serous ovarian carcinoma. PLoS One (2012) 1.76

Spectrum of somatic mitochondrial mutations in five cancers. Proc Natl Acad Sci U S A (2012) 1.63

Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. Nat Genet (2016) 1.16

Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. Cancer Cell (2016) 1.06

Integrated genomic and molecular characterization of cervical cancer. Nature (2017) 0.96

Integrated Molecular Characterization of Uterine Carcinosarcoma. Cancer Cell (2017) 0.92

Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma. Cell (2017) 0.81

Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma. Cancer Cell (2017) 0.79

Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. Cancer Cell (2016) 0.76

Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. Cancer Cell (2017) 0.75